VBI Vaccines (NASDAQ:VBIV) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of VBI Vaccines (NASDAQ:VBIV) in a research note released on Monday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

VBI Vaccines Stock Performance

Shares of VBI Vaccines stock opened at $0.60 on Monday. VBI Vaccines has a one year low of $0.45 and a one year high of $10.47. The company has a market cap of $14.28 million, a PE ratio of -0.05 and a beta of 1.92. The business has a 50-day simple moving average of $0.61 and a 200-day simple moving average of $0.63.

Hedge Funds Weigh In On VBI Vaccines

A number of large investors have recently modified their holdings of VBIV. Engineers Gate Manager LP purchased a new position in shares of VBI Vaccines in the 1st quarter worth about $26,000. Point72 Hong Kong Ltd acquired a new stake in VBI Vaccines during the 2nd quarter valued at approximately $29,000. Barclays PLC grew its stake in VBI Vaccines by 89.9% during the 1st quarter. Barclays PLC now owns 98,337 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 46,566 shares in the last quarter. Voya Investment Management LLC grew its stake in VBI Vaccines by 29.7% during the 4th quarter. Voya Investment Management LLC now owns 95,428 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 21,824 shares in the last quarter. Finally, BNP Paribas Arbitrage SA grew its stake in VBI Vaccines by 208.7% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 47,668 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 32,227 shares in the last quarter. 12.26% of the stock is currently owned by hedge funds and other institutional investors.

About VBI Vaccines

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.